Our Assets.
Features.
Since 2018, NETRI has capitalized on its growing expertise to build a strong base of continuously expanding technical and production capabilities, as well as an international commercial footprint.
• Know-how assets
• Production assets
• Commercial assets
Know-how Assets.
NETRI has developed recognized know-how in microfluidics neuro-engineering, cell culture of human induced pluripotent stem cells, and digital tools development. Since the beginning, we have nurtured our skillsets in multiple microfluidics, cells and readouts protocols: immunofluorescence, dedicated biomarkers, LC/MS, and ELISA assays in microfluidics devices.
• Open innovation developement with our clients
• 9 cell seeding and culture/co-culture protocols
• 42 immunostaining protocols
• Electrophysiological recording using MicroElectrodes Arrays
• Scientific valorisation through peer-reviewed publications, poster, international conferences
Production Assets.
NETRI manufactures devices and models using its pilot production units of microfluidic devices and cell culture automated labs. With more than 200 m² of production platform, 3 devices are marketed and divided into 3 options. Five types of neurons human cells derived from stem cells as well as primary keratinocytes and endothelial cells are marketable with our devices. In 2024, with the construction of its production site, NETRI will increase the production capacity of its pre-industrial pilot units with:
• 100 m² of ISO 8 laboratory for its ready-to-use devices production unit
• 100 m² of P2 laboratory for its pre-industrial unit of pre-cultivated devices
• 2 secure computing bays, for its artificial intelligence data analysis production unit
• A dedicated area for its biobank
Commercial Assets.
NETRI holds 9 proprietary patents and undisclosed manufacturing skillsets. Our devices are compatible with all cell types and we have established contracted partnerships with key cell suppliers, technological enablers, and high-content screening imaging and lab automation providers. NETRI has established strategic partnerships to create commercial alliances, growth relays and provide innovative combined solutions to the healthcare ecosystem.
• Axion BioSytems, technology supplier
• Axol Biosciences, human iPSC-derived cells supplier
• ETAP-Lab, a CRO specialized in in vivo NDD
